Haleon PLC anticipates a slow start to 2026 with first-quarter sales impacted by a weak cough and cold season in Europe and North America, leading to lower demand for respiratory products. Analysts from Citi and UBS forecast organic sales growth around 2.2%, below consensus, with UBS predicting flat reported revenue of £2.86 billion due to foreign exchange effects. However, growth is expected to pick up in the second half of the year, driven by a US 'shelf reset' and easing seasonal comparisons, with oral health products like Sensodyne supporting performance. Margins are also forecast to improve, aided by cost savings and pricing, while geopolitical tensions have not materially disrupted operations so far.
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing deman...
The global hybrid robots market is projected to grow from $5.68 billion in 2026 to $10.03 billion by 2030, with a CAGR of 15.3%. Growth is fueled by advances in AI, autonomous operations, and smart manufacturing, alongside rising demand for robots in...
